472 terminated. 472 Phase 1, 163 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 472 | Terminated 472 |
| Phase 2 | 163 | Terminated 163 |
Follow Neuroectodermal Tumors: new trials by email Literature Review of Neuroectodermal Tumors trials Research Report on Neuroectodermal Tumors
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Phase 1-1b Study to Evaluate the Safety, Efficacy and Dosimetry of Study Drug A9-3408 in Subjects With Metastatic Melanoma [225Ac]Ac-A9-3408, [68Ga]Ga-A9T-3202 - Melanoma Metastatic, Uveal Melanoma, Metastatic | Phase 1 | Terminated | Alpha-9 Oncology USA Inc. | 5 | 2025-11-19 | 2026-08-31 |
| Exploratory Study of Inhaled Afatinib Dimaleate PK Profile Afatinib Dimaleat, inhalation of afatinib dimaleate - Lung Cancer, Oral Cancer | Phase 1 | Terminated | Petrov, Andrey | 4 | 2025-11-09 | 2026-06-03 |
| NG2 and DLL3 CAR-T Cells Targeting Melanoma NG2 and DLL3 CAR-T cells - Melanoma | Phase 1 / Phase 2 | Terminated | Shenzhen Geno-Immune Medical Institute | 100 | 2025-09-01 | 2026-08-24 |
| Study of 225Ac-SS0110 in Subjects With ES-SCLC or MCC (SANTANA-225 ) 225Ac-SSO110 + SoC, Atezolizumab, Durvalumab - Small Cell Lung Cancer Extensive Stage, Merkel Cell Carcinoma | Phase 1 / Phase 2 | Terminated | Ariceum Therapeutics GmbH | 2 | 2025-07-01 | 2026-02-05 |
| A Study to Learn About the Study Medicine Called PF-08046032 in People With Advanced Cancers PF-08046032, Sasanlimab - Peripheral T Cell Lymphoma, Diffuse Large B-cell Lymphoma | Phase 1 | Terminated | Pfizer | 6 | 2025-05-08 | 2026-05-08 |
| A Clinical Trial of PF-08046037 Alone or With Sasanlimab in Patients With Advanced or Metastatic Malignancies PF-08046037, sasanlimab - Carcinoma, Non Small Cell Lung, Carcinoma, Pancreatic Ductal | Phase 1 | Terminated | Pfizer | 8 | 2025-05-06 | 2026-04-23 |
| A Study to Learn About the Study Medicine Called PF-08046031 in Advanced Melanoma and Other Solid Tumors PF-08046031 - Malignant Melanoma, Melanoma | Phase 1 | Terminated | Pfizer | 11 | 2025-05-01 | 2026-03-18 |
| A Study to Learn About PF-07921585 Alone or With Other Anti-cancer Medicines in People With Cancer PF-07921585, Sasanlimab - Non Small Cell Lung Cancer, Bladder Cancer | Phase 1 | Terminated | Pfizer | 4 | 2024-11-11 | 2026-03-23 |
| A Study to Learn About How Different Amounts of the Study Medicine PF-07826390 Act in the Body of People With Cancer When Taken Alone or With Other Anti-cancer Medicines. PF-07826390, sasanlimab, SOC (anti-PD-1 + platinum -based chemo) - Neoplasms, Non-small-cell Lung Cancer | Phase 1 | Terminated | Pfizer | 10 | 2024-09-06 | 2026-02-23 |
| Re-Administration of C134 in Patients With Recurrent GBM (C134-HSV-1) C134 Re-Administration - Recurrent Malignant Glioma, Glioblastoma Multiforme of Brain | Phase 1 | Terminated | University of Alabama at Birmingham | 1 | 2024-06-21 | 2026-01-22 |
| A Phase 1a/1b Study of ACTM-838 in Patients With Advanced Solid Tumors ACTM-838 - Solid Tumor | Phase 1 | Terminated | Actym Therapeutics, Inc. | 10 | 2024-06-05 | 2025-10-15 |
| A Study of ASP1012 in Adults With Solid Tumors ASP1012, Pembrolizumab - Solid Tumor | Phase 1 | Terminated | Astellas Pharma Global Development, Inc. | 15 | 2024-05-15 | 2026-08-27 |
| Study of DCC-3084 in Participants With Advanced Malignancies Driven by the Mitogen-Activated Protein Kinase (MAPK) Pathway DCC-3084 - Advanced Solid Tumor, RAF Mutation | Phase 1 | Terminated | Deciphera Pharmaceuticals, LLC | 29 | 2024-05-14 | 2026-03-05 |
| A Study in Advanced/Metastatic Solid Tumors With the Study Medicine (PF-07329640) When Given Alone or In Combination PF-07329640, sasanlimab, bevacizumab - Advanced or Metastatic Solid Tumors, Non-Small Cell Lung Cancer | Phase 1 | Terminated | Pfizer | 4 | 2024-05-09 | 2024-11-06 |
| NM32-2668 in Adult Patients With Selected Advanced Solid Tumors NM32-2668 - Ovarian Carcinoma, Fallopian Tube Carcinoma | Phase 1 | Terminated | Numab Therapeutics AG | 11 | 2024-05-01 | 2025-07-23 |
| Study of Autologous Tumor-Infiltrating Lymphocytes in Pediatric, Adolescent, and Young Adult Participants LN-145/LN-144 - Soft Tissue Sarcoma, Primary Central Nervous System Carcinoma | Phase 1 | Terminated | Iovance Biotherapeutics, Inc. | 5 | 2024-03-28 | 2026-10-16 |
| A Study of PF-07820435 as a Single Agent and in Combination in Participants With Advanced Solid Tumors PF-07820435, Sasanlimab - Neoplasms, Non-small-cell Lung Cancer | Phase 1 | Terminated | Pfizer | 9 | 2024-02-08 | 2025-09-17 |
| Study of IK-595 in RAS- or RAF-altered Advanced Tumors IK-595 - Solid Tumor, Adult, Colorectal Cancer | Phase 1 | Terminated | Ikena Oncology | 75 | 2023-12-18 | 2025-09-19 |
| IMM60 and Pembrolizumab in Melanoma and NSCLC IMM60, Pembrolizumab - Non-small Cell Lung Cancer, Melanoma | Phase 1 / Phase 2 | Terminated | iOx Therapeutics | 1 | 2023-11-15 | 2024-04-24 |
| Study of MT-8421 as Monotherapy and in Combination With Nivolumab in Patients With Selected Advanced Solid Cancer Types MT-8421, Nivolumab - Non Small Cell Lung Cancer, Hepatocellular Carcinoma | Phase 1 | Terminated | Molecular Templates, Inc. | 15 | 2023-11-01 | 2024-11-01 |
Showing 20 of 472. Sign in to see all of them.
Melanoma (244) · Glioblastoma (112) · Carcinoma, Non-Small-Cell Lung (79) · Glioma (64) · Brain Neoplasms (56) · Neoplasms (54) · Neoplasm Metastasis (53) · Astrocytoma (46) · Carcinoma, Renal Cell (46) · Colorectal Neoplasms (40) · Squamous Cell Carcinoma of Head and Neck (38) · Neuroblastoma (33) · Sarcoma (32) · Ovarian Neoplasms (31) · Gliosarcoma (30)
Neoplasms, Nerve Tissue (472) · Neoplasms by Histologic Type (471) · Neoplasms, Germ Cell and Embryonal (471) · Neoplasms (418) · Neoplasms by Site (350) · Neoplasms, Glandular and Epithelial (298) · Neuroendocrine Tumors (268) · Skin Diseases (254) · Skin and Connective Tissue Diseases (254) · Nevi and Melanomas (252) · Skin Neoplasms (233) · Neoplasms, Neuroepithelial (202) · Glioma (108) · Carcinoma (102)
Temozolomide (46) · pembrolizumab (36) · Cyclophosphamide (33) · Ipilimumab (33) · Nivolumab (24) · Radiotherapy (21) · fludarabine (17) · Radiation (13) · Interleukin-2 (12) · aldesleukin (12) · Bevacizumab (11) · Radiosurgery (9) · poly ICLC (9) · spartalizumab (9) · Filgrastim (8)
National Cancer Institute (NCI) (36) · M.D. Anderson Cancer Center (24) · Pfizer (18) · Novartis Pharmaceuticals (14) · Pediatric Brain Tumor Consortium (8) · Fred Hutchinson Cancer Center (6) · Incyte Corporation (6) · Mayo Clinic (6) · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (5) · Bristol-Myers Squibb (4) · Craig L Slingluff, Jr (4) · Ludwig Institute for Cancer Research (4) · Seagen Inc. (4) · University of Florida (4) · Washington University School of Medicine (4)
United States (402) · France (43) · Spain (42) · Canada (30) · United Kingdom (30) · Australia (29) · Italy (25) · Germany (22) · Belgium (21) · Netherlands (17) · Switzerland (13) · Japan (12) · South Korea (12) · Denmark (8) · Taiwan (8)
Steven A Rosenberg, M.D. (8) · David Ashley, MBBS, FRACP, PhD (3) · David S Schrump, M.D. (3) · Adil Daud, M.D. (2) · Annick Desjardins, MD, FRCPC (2) · Aude Chapuis (2) · Craig L. Slingluff, Jr., MD (2) · Daniel Landi, MD (2) · David Spriggs, MD (2)
PMID 31401903, PMID 12684398, PMID 12749708, PMID 17293590, PMID 18425516, PMID 19065567, PMID 20305636, PMID 20930628, PMID 21516509, PMID 22056381, PMID 23071222, PMID 23171508, PMID 23377668, PMID 23415641, PMID 23861247, PMID 24025700, PMID 24327518, PMID 24410126, PMID 24456794, PMID 24577748, PMID 24792486, PMID 25062770, PMID 25086465, PMID 25105369, PMID 25252722, PMID 25695689, PMID 26500235, PMID 27087489, PMID 27424289, PMID 28053024, PMID 28062705, PMID 28357727, PMID 28672195, PMID 29322091, PMID 29350463, PMID 29383130, PMID 29552014, PMID 29735994, PMID 29846250, PMID 29872570, PMID 30154193, PMID 30232146, PMID 30297385, PMID 30711772, PMID 30796035, PMID 30894212, PMID 30989436, PMID 31101621, PMID 31215818, PMID 31527168
2019 (11), 2015 (7), 2018 (6), 2017 (5), U01CA062490 (5), U01CA081457 (5), 2023 (4), P30CA006516 (4), P30CA043703 (4), UM1CA137443 (4), 2009 (3), P30CA015704 (3), UM1CA186709 (3), 2014 (2), 2016 (2)